Literature DB >> 18413646

Phenotypic and genetic characterization of circulating tumor cells by combining immunomagnetic selection and FICTION techniques.

María Campos1, Celia Prior, Fernando Warleta, Isabel Zudaire, Jesús Ruíz-Mora, Raúl Catena, Alfonso Calvo, José J Gaforio.   

Abstract

The presence of circulating tumor cells (CTCs) in breast cancer patients has been proven to have clinical relevance. Cytogenetic characterization of these cells could have crucial relevance for targeted cancer therapies. We developed a method that combines an immunomagnetic selection of CTCs from peripheral blood with the fluorescence immunophenotyping and interphase cytogenetics as a tool for investigation of neoplasm (FICTION) technique. Briefly, peripheral blood (10 ml) from healthy donors was spiked with a predetermined number of human breast cancer cells. Nucleated cells were separated by double density gradient centrifugation of blood samples. Tumor cells (TCs) were immunomagnetically isolated with an anti-cytokeratin antibody and placed onto slides for FICTION analysis. For immunophenotyping and genetic characterization of TCs, a mixture of primary monoclonal anti-pancytokeratin antibodies was used, followed by fluorescent secondary antibodies, and finally hybridized with a TOP2A/HER-2/CEP17 multicolor probe. Our results show that TCs can be efficiently isolated from peripheral blood and characterized by FICTION. Because genetic amplification of TOP2A and ErbB2 (HER-2) in breast cancer correlates with response to anthracyclines and herceptin therapies, respectively, this novel methodology could be useful for a better classification of patients according to the genetic alterations of CTCs and for the application of targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413646      PMCID: PMC2430160          DOI: 10.1369/jhc.2008.951111

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  44 in total

1.  Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.

Authors:  T A Järvinen; M Tanner; V Rantanen; M Bärlund; A Borg; S Grénman; J Isola
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

2.  Simultaneous detection of HER2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer.

Authors:  Christian Lottner; Stephan Schwarz; Simone Diermeier; Arndt Hartmann; Ruth Knuechel; Ferdinand Hofstaedter; Gero Brockhoff
Journal:  J Pathol       Date:  2005-04       Impact factor: 7.996

3.  Feasibility of simultaneous fluorescence immunophenotyping and fluorescence in situ hybridization study for the detection of estrogen receptor expression and deletions of the estrogen receptor gene in breast carcinoma cell lines.

Authors:  Y Zhang; R Siebert; P Matthiesen; S Harder; M Theile; S Scherneck; B Schlegelberger
Journal:  Virchows Arch       Date:  2000-03       Impact factor: 4.064

4.  Genomic analysis of single cytokeratin-positive cells from bone marrow reveals early mutational events in breast cancer.

Authors:  Julian A Schardt; Manfred Meyer; Claudia H Hartmann; Falk Schubert; Oleg Schmidt-Kittler; Christine Fuhrmann; Bernhard Polzer; Marco Petronio; Roland Eils; Christoph A Klein
Journal:  Cancer Cell       Date:  2005-09       Impact factor: 31.743

Review 5.  Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer.

Authors:  Tero A H Järvinen; Edison T Liu
Journal:  Curr Cancer Drug Targets       Date:  2006-11       Impact factor: 3.428

Review 6.  Genomics and circulating tumor cells: promising tools for choosing and monitoring adjuvant therapy in patients with early breast cancer?

Authors:  Luc Dirix; Peter Van Dam; Peter Vermeulen
Journal:  Curr Opin Oncol       Date:  2005-11       Impact factor: 3.645

7.  Mantle cell lymphoma with plasma cell differentiation.

Authors:  Ken H Young; Wing C Chan; Kai Fu; Javeed Iqbal; Warren G Sanger; Anne Ratashak; Timothy C Greiner; Dennis D Weisenburger
Journal:  Am J Surg Pathol       Date:  2006-08       Impact factor: 6.394

8.  Comprehensive copy number profiles of breast cancer cell model genomes.

Authors:  Ashleen Shadeo; Wan L Lam
Journal:  Breast Cancer Res       Date:  2006-01-03       Impact factor: 6.466

Review 9.  Recent translational research: circulating tumor cells in breast cancer patients.

Authors:  Volkmar Müller; Daniel F Hayes; Klaus Pantel
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

10.  Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.

Authors:  J Hannemann; P Kristel; H van Tinteren; M Bontenbal; Q G C M van Hoesel; W M Smit; M A Nooij; E E Voest; E van der Wall; P Hupperets; E G E de Vries; S Rodenhuis; M J van de Vijver
Journal:  Br J Cancer       Date:  2006-10-31       Impact factor: 7.640

View more
  7 in total

1.  High-throughput selection, enumeration, electrokinetic manipulation, and molecular profiling of low-abundance circulating tumor cells using a microfluidic system.

Authors:  Udara Dharmasiri; Samuel K Njoroge; Małgorzata A Witek; Morayo G Adebiyi; Joyce W Kamande; Mateusz L Hupert; Francis Barany; Steven A Soper
Journal:  Anal Chem       Date:  2011-02-14       Impact factor: 6.986

Review 2.  The biology of circulating tumor cells.

Authors:  K Pantel; M R Speicher
Journal:  Oncogene       Date:  2015-06-08       Impact factor: 9.867

Review 3.  Is Tissue Still the Issue? The Promise of Liquid Biopsy in Uveal Melanoma.

Authors:  Daniël P de Bruyn; Aaron B Beasley; Robert M Verdijk; Natasha M van Poppelen; Dion Paridaens; Ronald O B de Keizer; Nicole C Naus; Elin S Gray; Annelies de Klein; Erwin Brosens; Emine Kiliç
Journal:  Biomedicines       Date:  2022-02-21

4.  Detection of circulating tumor cells in blood of metastatic breast cancer patients using a combination of cytokeratin and EpCAM antibodies.

Authors:  Ulrike Weissenstein; Agnes Schumann; Marcus Reif; Susanne Link; Ulrike D Toffol-Schmidt; Peter Heusser
Journal:  BMC Cancer       Date:  2012-05-30       Impact factor: 4.430

5.  Negative enrichment by immunomagnetic nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients.

Authors:  Zhian Liu; Alberto Fusi; Eva Klopocki; Alexander Schmittel; Ingeborg Tinhofer; Anika Nonnenmacher; Ulrich Keilholz
Journal:  J Transl Med       Date:  2011-05-19       Impact factor: 5.531

6.  Detection of micrometastases in peripheral blood of non-small cell lung cancer with a refined immunomagnetic nanoparticle enrichment assay.

Authors:  Qing Li; Hui Qi; Han-Xin Zhou; Chun-Yan Deng; Hai Zhu; Jin-Feng Li; Xi-Li Wang; Fu-Rong Li
Journal:  Int J Nanomedicine       Date:  2011-09-29

7.  Screening and Molecular Analysis of Single Circulating Tumor Cells Using Micromagnet Array.

Authors:  Yu-Yen Huang; Peng Chen; Chun-Hsien Wu; Kazunori Hoshino; Konstantin Sokolov; Nancy Lane; Huaying Liu; Michael Huebschman; Eugene Frenkel; John X J Zhang
Journal:  Sci Rep       Date:  2015-11-05       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.